OncoMatch/Clinical Trials/NCT05467748
EZH2 Inhibitor, Tulmimetostat, and PD-1 Blockade for Treatment of Advanced Non-small Cell Lung Cancer
Is NCT05467748 recruiting? Yes, currently enrolling (May 2026). This Phase 1/2 trial studies Tulmimetostat for non small cell lung cancer.
Treatment: Tulmimetostat — This is an open label, single arm, phase Ib/II clinical trial of checkpoint blockade, pembrolizumab and EZH2 inhibitor, tulmimetostat combination therapy for patients with advanced non-small cell lung cancer who have progressed from front or second-line treatment. Patients will be enrolled at multiple Veterans Affairs Medical Centers.
Check if I qualifyExtracted eligibility criteria
Cancer type
Small Cell Lung Cancer
Biomarker criteria
Excluded: EGFR altered
EGFR or ALK altered patients [excluded]
Excluded: ALK altered
EGFR or ALK altered patients [excluded]
Disease stage
Metastatic disease required
advanced non-small cell lung cancer
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: anti-PD-1 therapy — monotherapy or in combination
Participants must have progressed on treatment with an anti-PD-1/L1 mAb administered either as monotherapy or in combination with other checkpoint inhibitors or other therapies
Cannot have received: EZH2 inhibitor (tulmimetostat)
Prior exposure to tulmimetostat or other EZH2 inhibitors
Cannot have received: immunotherapy
Immunotherapy naïve patients [excluded]
Lab requirements
Blood counts
Absolute neutrophil counts (ANC) 1500/mm3; Platelet count 100,000/mm3; Hemoglobin 9 g/dL without need for hematopoietic growth factor or transfusion support; Prothrombin time (PT) 1.5 x ULN and INR 1.3; Partial thromboplastin time (PTT) 1.5 ULN
Kidney function
Serum creatinine 1.5 x ULN, or 24-hour creatinine clearance 30 cc/min
Liver function
Serum bilirubin 1.5 ×ULN OR direct bilirubin ULN for participants with total bilirubin levels >1.5 × ULN; AST 2.5 ULN or 5XULN for subjects with liver metastases; ALT 2.5 ULN or 5XULN for subjects with liver metastases; Alkaline phosphatase 2.5 X ULN of liver fraction if 2.5 X ULN; Serum albumin 2.5g/dL
Adequate organ function. (must be within 10 days prior to start of study intervention)...
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- VA Long Beach Healthcare System, Long Beach, CA · Long Beach, California
- VA Northern California Health Care System, Mather, CA · Sacramento, California
- VA San Diego Healthcare System, San Diego, CA · San Diego, California
- VA Ann Arbor Healthcare System, Ann Arbor, MI · Ann Arbor, Michigan
- Michael E. DeBakey VA Medical Center, Houston, TX · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify